Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan · Delayed Price · Currency is JPY 1,678.00
-15.50 (-0.92%)
Jul 18, 2025, 3:30 PM JST
Santen Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 300,004 | 301,965 | 279,037 | 266,257 | 249,605 | Upgrade | |
Revenue Growth (YoY) | -0.65% | 8.22% | 4.80% | 6.67% | 3.33% | Upgrade |
Cost of Revenue | 128,977 | 123,256 | 112,950 | 109,671 | 98,221 | Upgrade |
Gross Profit | 171,027 | 178,709 | 166,087 | 156,586 | 151,384 | Upgrade |
Selling, General & Admin | 83,299 | 86,880 | 134,072 | 120,610 | 113,586 | Upgrade |
Research & Development | 24,103 | 25,416 | - | - | - | Upgrade |
Other Operating Expenses | 1,638 | -282 | -3,285 | 101 | -15,710 | Upgrade |
Operating Expenses | 122,732 | 126,524 | 130,787 | 120,711 | 97,876 | Upgrade |
Operating Income | 48,295 | 52,185 | 35,300 | 35,875 | 53,508 | Upgrade |
Interest Expense | -1,083 | -831 | -476 | -249 | -159 | Upgrade |
Interest & Investment Income | 1,623 | 1,262 | 1,086 | 1,063 | 928 | Upgrade |
Earnings From Equity Investments | -685 | -7,575 | -2,362 | -1,604 | -358 | Upgrade |
Currency Exchange Gain (Loss) | 1,651 | -121 | -663 | -959 | -910 | Upgrade |
Other Non Operating Income (Expenses) | 15 | -198 | -118 | 371 | -120 | Upgrade |
EBT Excluding Unusual Items | 49,816 | 44,722 | 32,767 | 34,497 | 52,889 | Upgrade |
Merger & Restructuring Charges | - | -5,829 | -3,225 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -708 | -1,046 | -228 | 800 | -119 | Upgrade |
Gain (Loss) on Sale of Assets | -286 | 738 | -554 | 412 | -102 | Upgrade |
Asset Writedown | -1,302 | -7,547 | -34,508 | 245 | -40,250 | Upgrade |
Legal Settlements | - | -410 | -51 | -338 | - | Upgrade |
Other Unusual Items | -39 | -755 | - | - | - | Upgrade |
Pretax Income | 47,481 | 29,873 | -5,799 | 35,616 | 12,418 | Upgrade |
Income Tax Expense | 11,628 | 3,171 | 9,184 | 8,427 | 5,773 | Upgrade |
Earnings From Continuing Operations | 35,853 | 26,702 | -14,983 | 27,189 | 6,645 | Upgrade |
Minority Interest in Earnings | 403 | -60 | 35 | 29 | 185 | Upgrade |
Net Income | 36,256 | 26,642 | -14,948 | 27,218 | 6,830 | Upgrade |
Preferred Dividends & Other Adjustments | 9 | 8 | 7 | 6 | 4 | Upgrade |
Net Income to Common | 36,247 | 26,634 | -14,955 | 27,212 | 6,826 | Upgrade |
Net Income Growth | 36.09% | - | - | 298.51% | -71.08% | Upgrade |
Shares Outstanding (Basic) | 349 | 367 | 387 | 400 | 399 | Upgrade |
Shares Outstanding (Diluted) | 350 | 368 | 387 | 400 | 400 | Upgrade |
Shares Change (YoY) | -5.01% | -4.98% | -3.26% | 0.02% | 0.03% | Upgrade |
EPS (Basic) | 103.98 | 72.59 | -38.60 | 68.07 | 17.09 | Upgrade |
EPS (Diluted) | 103.68 | 72.37 | -38.60 | 67.97 | 17.06 | Upgrade |
EPS Growth | 43.26% | - | - | 298.44% | -71.09% | Upgrade |
Free Cash Flow | 54,266 | 63,330 | 19,870 | 28,699 | 34,669 | Upgrade |
Free Cash Flow Per Share | 155.18 | 172.03 | 51.29 | 71.67 | 86.59 | Upgrade |
Dividend Per Share | 36.000 | 33.000 | 32.000 | 32.000 | 28.000 | Upgrade |
Dividend Growth | 9.09% | 3.13% | - | 14.29% | 3.70% | Upgrade |
Gross Margin | 57.01% | 59.18% | 59.52% | 58.81% | 60.65% | Upgrade |
Operating Margin | 16.10% | 17.28% | 12.65% | 13.47% | 21.44% | Upgrade |
Profit Margin | 12.08% | 8.82% | -5.36% | 10.22% | 2.73% | Upgrade |
Free Cash Flow Margin | 18.09% | 20.97% | 7.12% | 10.78% | 13.89% | Upgrade |
EBITDA | 66,243 | 70,363 | 52,549 | 52,930 | 70,276 | Upgrade |
EBITDA Margin | 22.08% | 23.30% | 18.83% | 19.88% | 28.16% | Upgrade |
D&A For EBITDA | 17,948 | 18,178 | 17,249 | 17,055 | 16,768 | Upgrade |
EBIT | 48,295 | 52,185 | 35,300 | 35,875 | 53,508 | Upgrade |
EBIT Margin | 16.10% | 17.28% | 12.65% | 13.47% | 21.44% | Upgrade |
Effective Tax Rate | 24.49% | 10.62% | - | 23.66% | 46.49% | Upgrade |
Advertising Expenses | 13,310 | 18,278 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.